ABHI Diabetes Statement on Access to Hybrid-Closed Loop (HCL) Technologies for People who are Pregnant or Planning to Become Pregnant.
Topic : Position Papers Type : Briefing
People with diabetes should have the choice to use the most appropriate technology to meet their needs. This includes, people who are pregnant or planning to become pregnant as recommended in NICE guidance on the use of hybrid-closed loop (HCL) systems for people with Type 1 diabetes.
Industry partners recognise the need to be flexible and support people who are pregnant, or planning to become pregnant, to have equitable and timely access to HCL technology. This may mean transitioning between technologies, managed through a transparent process, case-by-case, and achieved without delay.
In all instances, we encourage people with diabetes who require access to technology to discuss their needs with their Health Care Professional (HCP) to help them make an informed decision.
This position is supported by ABHI Diabetes companies:
- Abbott Laboratories Ltd
- Air Liquide Healthcare
- Ascend Care Ltd
- Ascensia Diabetes Care UK Ltd
- Dexcom
- Embecta UKI Ltd
- Insulet International Ltd
- Medtronic Ltd
- Medtrum Ltd
- Roche Diabetes Care Ltd
- Ypsomed Ltd.